BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

Akums secures European CEP approval for Cefpodoxime Proxetil

The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner

CORONA Remedies receives EU-GMP certification for hormone facility

Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets

Morepen Labs posts strong Q4 FY26 net profit

For the full year, standalone gross revenue crossed Rs. 1,700 crore

ZIM Laboratories wins European regulatory milestone with anticoagulant approval in Italy

The approval was granted by Agenzia Italiana del Farmaco

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies

Caplin Steriles receives USFDA approval for generic foscarnet sodium injection

Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months

Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore